One injection of modified RNA that activates T cells targeting CD19 supports long-term removal of cancerous B cells

A single lipid-nanoparticle dose of modified saRNA encoding a CD19 BiTE produced prolonged BiTE expression and cleared malignant B cells in a leukemia rechallenge model.

This preclinical RNA-platform study tested m5C-modified saRNA-BiTE in vitro and in an acute lymphoblastic leukemia rechallenge model, with expression lasting 6 weeks and recurrence prevented for 3 months.

The findings come from preclinical models, so clinical safety, immune effects, dosing control, and durability in patients are unknown.